

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2025/186553 A8

(43) International Publication Date
11 September 2025 (11.09.2025)

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 31/444 (2006.01)
C07D 401/14 (2006.01)

(21) International Application Number:

PCT/GB2025/050426

(22) International Filing Date:

04 March 2025 (04.03.2025)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2403113.0 04 March 2024 (04.03.2024) GB

(71) Applicant: **APOLLO AP30 LIMITED** [GB/GB]; 3rd
Floor, 22 Station Road, Cambridge CB1 2JD (GB).

(72) Inventors: **GLOSSOP, Melanie**; c/o Apollo Therapeutics
Limited, 3rd Floor, 22 Station Road, Cambridge CB1 2JD

(GB). **FLANAGAN, Neil**; c/o Apollo Therapeutics Limited,
3rd Floor, 22 Station Road, Cambridge CB1 2JD (GB).

(74) Agent: **ABEL & IMRAY LLP**; Westpoint Building, James
Street West, Bath Bath and North East Somerset BA1 2DA
(GB).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN,
WS, ZA, ZM, ZW.

(54) Title: NOVEL CRYSTALLINE COMPOUNDS




Figure 2

(57) **Abstract:** The invention provides a crystalline form of N-{4-[2-(2-aminopyrimidin-5-yl)ethynyl]-3- fluoropyridin-2-yl}-5-chloro-2-methoxypyridine-3-sulfonamide characterized by a powder X- ray diffractogram (XRPD) having characteristic peaks at $2\theta = 8.6 \pm 0.2^\circ$, $13.5 \pm 0.2^\circ$, $22.6 \pm 0.2^\circ$ and $24.7 \pm 0.2^\circ$. The invention further provides pharmaceutical compositions comprising the 5 crystalline form of the invention and uses of the crystalline form and the compositions. The crystalline form and the compositions are useful for the treatment or prevention of a variety of conditions, particularly cancer.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:

02 October 2025 (02.10.2025)

(15) Information about Correction:

see Notice of 02 October 2025 (02.10.2025)